{"favorite_id": 3012, "calc_type": "calculator", "dosing": false, "full_title_en": "Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma", "short_title_en": "Fuhrman Nuclear Grade", "medium_description_en": "Provides prognostic grading system for tumor cells based on physical cellular appearance.", "short_description_en": "Prognose RCC based on cellular appearance.", "before_use": "", "instructions_en": "", "slug": "fuhrman-nuclear-grade-clear-cell-renal-carcinoma", "logic_language": "javascript", "md5": "5ecd25b779e088396d7d685be795a676", "cmeVersion": null, "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "publishedAt": "2022-04-21T20:29:12.166Z", "vuid": "9ad84d42-9f6c-4e4c-969e-ef6f719b2ba5", "versionNumber": 1, "isVisibleInListView": true, "disabled": false, "replacement_calc_id": null, "disabled_reason": null, "search_abbreviation_en": ["rcc", "renal", "kidney cancer", "kidney", "nucleus", "nucleoli", "chomatic"], "seo": {"meta_description_en": "Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma provides prognostic grading system for tumor cells based on physical cellular appearance.", "keywords_en": "fuhrman, fuhrman score, rcc score, score, fuhrman score, rcc prognosis, fuhrman cancer score, fuhrman cancer prognosis, fuhrman rcc score, renal cell carcinoma score, fuhrman kidney cancer, kidney cancer score, metastatic rcc, localized rcc, tnm rcc, tnm fuhrman, tnm, fuhrman radiology, fuhrman grade, fuhrman diagnosis, fuhrman grading system, nuclear grading, nuclear grading system, fuhrman nuclear"}, "content": {"reviewer": {"expert_name": []}, "related_resources": {"interests": [{"link": "https://www.mdcalc.com/rcc-renal-cell-carcinoma-practice-pearls", "text": "Practice Pearls: Renal Cell Carcinoma", "description": ""}]}, "how_to_use": {"use_case_en": "<p>Patients with clear cell <abbr title=\"Renal Cell Carcinoma\">RCC</abbr> and pathology assessment available.</p>", "pearls_pitfalls_en": "<p>The Fuhrman Nuclear Grade is a pathology component of renal cell cancers and an independent predictor of cancer-specific survival. Virtually all data are from chart or database reviews and predate modern targeted therapies, but typically worsening nuclear grade correlates with worsening prognosis.</p>", "why_use_en": "<p>There are no validated scoring systems for predicting survival in clear cell RCC. Using the Fuhrman grade or scoring systems that integrate it may help delineate categories of survival time better than clinical judgment alone.</p>"}, "next_steps": {"advice_en": "<p>The Fuhrman grade, like most other predictors for clear cell RCC prognosis, has not been prospectively tested and validated. However retrospective findings across studies are fairly consistent and Fuhrman grade is now a necessary component of some other scoring systems. The numerical survival estimates, it should be noted, are likely to be different in patients receiving targeted modern therapy.</p>", "management_en": "<p>We are unaware of validated management algorithms using the score.</p>", "critical_actions_en": "<p>The Fuhrman grade is not known to be accurate for individual survival prediction and should be considered a general guide rather than a reliable predictor. Consistency in pathological grading is critical.</p>"}, "about": {"formula_en": "<ul>\n<li><strong>Grade 1</strong>\n<ul>\n<li>The nuclei of the tumor cells are small (&lt; 10 &micro;m), hyperchromatic, and round (resembling mature lymphocytes), with no visible nucleoli and little detail in the chromatin, as shown in the image below.</li>\n</ul>\n</li>\n<li><strong>Grade 2</strong>\n<ul>\n<li>Using the 10&times; objective, the nuclei of the tumor cells are slightly larger (15 &micro;m) with finely granular &ldquo;open&rdquo; chromatin but small, inconspicuous nucleoli (see the following image). The nucleoli are often present, and many appear as small chromocenters at 10&times; objective, with confirmation of their nature at higher power, but this does not count.</li>\n</ul>\n</li>\n<li><strong>Grade 3</strong>\n<ul>\n<li>Using the 10&times; objective, the nuclei of the tumor cells are larger (20 &micro;m in size) and may be oval in shape, with coarsely granular chromatin (see the image below). The nucleoli are easily unequivocally recognizable.</li>\n</ul>\n</li>\n<li><strong>Grade 4</strong>\n<ul>\n<li>The nuclei are pleomorphic with open chromatin or hyperchromatic and single or multiple macronucleoli, as depicted in the following image:</li>\n</ul>\n</li>\n</ul>\n<div class=\"authorimage\"><img src=\"https://cdn-web-img.mdcalc.com/fuhrman.jpeg\" class=\"alignnone size-full wp-image-1839\" alt=\"fuhrman nuclear grading scale\"></div>", "more_info_en": "<p>More recent studies have shown 2- and 3-tier grading systems for the Fuhrman Scale are equally as effective.</p>", "evidence_based_medicine_en": "", "references_list": {"Validation": [{"text": "Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005 Jan 1. 103(1):68-75.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/15573369"}, {"text": "Rioux-Leclercq N, Karakiewicz PI, Trinh QD, Ficarra, V, Cindolo L, et. al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer, 2007; 109: 868\u2013874. doi: 10.1002/cncr.22463", "href": "https://onlinelibrary.wiley.com/doi/10.1002/cncr.22463/full"}, {"text": "Klatte T, Anterasian C, Said JW, de Martino M, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol. 2010 Jun;183(6):2143-7. doi: 10.1016/j.juro.2010.02.023.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/20399450"}], "Outcomes": [], "Validations": [], "Original/Primary Reference": [{"text": "Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982 Oct;6(7):655-63.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/7180965"}], "Other References": [{"text": "Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001 Mar 15. 19(6):1649-57. ", "href": "https://www.ncbi.nlm.nih.gov/pubmed/11250993"}, {"text": "Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002 Dec 1. 20(23):4559-66.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/12454113"}, {"text": " Minervini A, et al. Prognostic value of nuclear grading in patients with intracapsular (pT1-pT2) renal cell carcinoma. Long-term analysis in 213 patients. Cancer. 2002 May 15;94(10):2590-5.", "href": "https://www.ncbi.nlm.nih.gov/pubmed/12173325"}], "Clinical Practice Guidelines": [], "Manufacturer Website": []}}, "creator": [{"qa_en": "", "approved": null, "name": "Dr. Susan A. Fuhrman", "creator_info": {"deceased": null, "about_en": "<p>Susan A. Fuhrman, MD, is a practicing clinical and anatomic pathologist in Columbus, Ohio. She is Director of Pathology and Lab at OhioHealth Central Laboratories. Dr. Fuhrman is best known in the scientific medical community for developing the Fuhrman Nuclear Grade for Clear Cell Renal Carcinoma.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-susan-a-fuhrman.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Fuhrman%20SA%5BAuthor%5D"}}, {"qa_en": "", "approved": null, "name": "Dr. Nathalie Rioux-Leclercq", "creator_info": {"deceased": null, "about_en": "<p>Nathalie Rioux-Leclercq, MD is the head of the Pathological Anatomy and Cytology Service, part of the Department of Pathology and a professor of medicine at Rennes University Hospital in France. Her research focuses on renal cell carcinoma. prostatic adenocarcinoma, proliferation and apoptosis in the tumor process, and was lead author on the validation and reclassification of the Fuhrman Grade.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/default.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Rioux-Leclercq+N%5BAuthor%5D"}}], "contributor": {"expert_name": []}}, "input_schema": [{"type": "radio", "name": "dia", "default": null, "show_points": false, "optional": false, "conditionality": null, "tips_en": "", "label_en": "Nuclear diameter", "option_fhir_rules": null, "options": [{"label": "Small (~10\u00b5m)", "value": 1}, {"label": "Larger (~15\u00b5m)", "value": 2}, {"label": "Even larger (~20\u00b5m)", "value": 3}], "mdcalc_info_concept": null}, {"type": "radio", "name": "shape", "default": null, "show_points": false, "optional": false, "conditionality": null, "tips_en": "", "label_en": "Nuclear shape", "option_fhir_rules": null, "options": [{"label": "Round, uniform", "value": 1}, {"label": "Irregularities in outline", "value": 2}, {"label": "Obvious irregular outline", "value": 3}], "mdcalc_info_concept": null}, {"type": "radio", "name": "nucleoli", "default": null, "show_points": false, "optional": false, "conditionality": null, "tips_en": "", "label_en": "Nucleoli", "option_fhir_rules": null, "options": [{"label": "Absent, inconspicuous", "value": 1}, {"label": "Visible at x400", "value": 2}, {"label": "Prominent at x100", "value": 3}], "mdcalc_info_concept": null}, {"type": "toggle", "name": "biz", "conditionality": null, "optional": true, "default": null, "label_en": "Bizarre often multilobed nuclei and/or spindle cells", "show_points": false, "tips_en": "", "option_fhir_rules": null, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "md_calc_info_concept": null}], "chief_complaint_en": ["Flank Pain", "Hematuria"], "specialty_en": ["Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine", "Nephrology", "Radiation Oncology", "Radiology", "Urology"], "purpose_en": ["Prognosis"], "system_en": ["Oncologic", "Renal"], "disease_en": ["Chemotherapy", "Renal Cell Carcinoma"], "tags": [], "versions": [], "related_calcs": [{"calcId": 2153, "short_title_en": "MSKCC/Motzer Criteria for RCC", "slug": "memorial-sloan-kettering-cancer-center-mskcc-motzer-score-metastatic-renal-cell-carcinoma-rcc"}, {"calcId": 3908, "short_title_en": "RENAL Nephrometry Score", "slug": "renal-nephrometry-score"}, {"calcId": 2154, "short_title_en": "SSIGN Score", "slug": "ssign-score-renal-cell-carcinoma-rcc"}]}